Workflow
BSX Q1 Earnings & Revenues Beat, Stock Up, 2025 View Raised
BSXBoston Scientific(BSX) ZACKS· ZACKS·2025-04-23 14:50

Core Viewpoint - Boston Scientific Corporation (BSX) reported strong first-quarter 2025 results, with adjusted earnings per share (EPS) of 75 cents, a 33.9% increase year-over-year, surpassing both the Zacks Consensus Estimate and the company's own guidance range [1][3][11] Financial Performance - The first-quarter revenue reached 4.66billion,reflectinga20.94.66 billion, reflecting a 20.9% year-over-year increase on a reported basis and 22.2% on an operational basis, exceeding the Zacks Consensus Estimate by 2.3% [3][11] - Reported EPS for the quarter was 45 cents, marking a 36.4% increase from the previous year [2] Revenue Breakdown - Revenue growth by region included a 31.1% increase in the United States, 5.5% in EMEA, 8.2% in Asia Pacific, and 4.4% in Latin America and Canada [4] - Emerging markets saw a reported revenue growth of 6.5% [4] Segment Performance - MedSurg segment revenues were 1.58 billion, up 11.7% year-over-year, with notable contributions from Endoscopy (673million),Urology(673 million), Urology (633 million), and Neuromodulation (271million)[6]Cardiovascularsegmentrevenuesreached271 million) [6] - Cardiovascular segment revenues reached 3.09 billion, a 26.2% increase, with Cardiology business sales totaling 2.43billion,up31.22.43 billion, up 31.2% [7] Margin Analysis - Gross margin expanded by 19 basis points to 68.8%, while adjusted operating margin increased by 127 basis points to 24.8% [8] Future Outlook - For 2025, BSX anticipates net sales growth of approximately 15-17% on a reported basis and 12-14% on an organic basis, with adjusted EPS expected in the range of 2.87-$2.94 [9][10] - The second quarter of 2025 is projected to see revenue growth of 17.5-19.5% on a reported basis [10] Strategic Developments - Recent acquisitions include SoniVie Ltd. and Bolt Medical, which are expected to positively impact the company's growth trajectory [12]